Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Status Active, not recruiting

Clinical Trial Summary

The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.

Clinical Trial Description

Primary objective: Assess clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma using progression free survival at 6 months (PFS-6). Secondary objective: : Assess safety and tolerability of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma. This is a Phase II study of two arms in participants with recurrent glioblastoma. Arm A will include participants with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy. Arm B is an exploratory arm of 10 participants who have failed prior anti-PD1 therapy. All patients will receive the study drug combination consisting of SurVaxM and pembrolizumab (PEM) with no randomization, stratification or dose escalation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04013672
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 19, 2020
Completion date	May 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05577091` - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT05284643` - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A
Recruiting	`NCT05039281` - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04988750` - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients	N/A
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT00503204` - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour	Phase 1
Completed	`NCT03216499` - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma	Phase 2
Not yet recruiting	`NCT04717999` - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma	N/A
Not yet recruiting	`NCT05540275` - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Phase 2
Recruiting	`NCT04528680` - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma	Phase 1/Phase 2
Completed	`NCT04044937` - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms	Phase 2
Recruiting	`NCT04888611` - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma	Phase 2
Completed	`NCT00390299` - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1
Recruiting	`NCT05463848` - Surgical Pembro +/- Olaparib w TMZ for rGBM	Phase 2
Active, not recruiting	`NCT04479241` - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma	Phase 2
Active, not recruiting	`NCT00777153` - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma	Phase 3
Withdrawn	`NCT05017610` - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma	Early Phase 1
Recruiting	`NCT04323046` - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Phase 1
Active, not recruiting	`NCT05324501` - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma	Phase 1
Withdrawn	`NCT05666349` - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	Phase 1